News
Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination
Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be
Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting
Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic
Biogen: Neue Hoffnung auf ein Alzheimer-Medikament treibt Aktie an!
Einer der größten Gewinner am US-Aktienmarkt war gestern das Papier von Biogen (WKN: 789617). Grund hierfür waren jedoch nicht in erster Linie die vorgelegten, sehr guten Quartalszahlen, sondern
Entpuppt sich Gilead Sciences doch noch als Value Trap?
Das Biotech-Unternehmen Gilead Sciences (WKN: 885823) habe ich noch gar nicht so lange auf dem Schirm und heute weiß ich, dass ich die Finger ganz davon hätte sein lassen sollen. Vor 15....
Here's How AbbVie Inc. Crushed It in 2017
It's been a tremendous year for AbbVie Inc. (NYSE: ABBV) shareholders. Shares of the Abbott spinoff have gained 56.5% this year as investors cheered a handful of important developments. As the....
3 Reasons to Own Pfizer's Stock in 2018
Despite losing nearly $30 billion in branded pharma sales due to the loss of exclusivity for key brands like Celebrex, Lipitor, Lyrica, and Viagra over the course of 2011 to 2020, Pfizer (NYSE:....
Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
It's been a great year for most investors, with the S&P 500 index rising close to 20% in 2017. But not every stock has performed that well. The stocks of two S&P 500 members,....
Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)
If AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled....
If I Could Only Buy 1 Healthcare Stock in January, It Would Be This One
Pfizer Inc. (NYSE: PFE) is the one healthcare stock I'd add to my portfolio in January. Why? The company's turning the corner back toward growth, its R&D team is delivering important wins, its....
3 Promising Cancer Immunotherapies to Watch in 2018
Any way you look at it, immunotherapies -- also known as immuno-oncology (I-O) drugs -- are hot commodities. Two of the top three cancer drugs projected to be the biggest winners in the next five....
3 Top Generic Drug Stocks to Consider Buying Now
Brand-name drugs tend to capture all the headlines, but did you know that nine out of every 10 prescriptions filled in the U.S. each year are generic? When added together, Americans spend spent....
New Gene Therapies Could Change Hemophilia Forever
At last week's American Society of Hemophilia conference, Spark Therapeutics (NASDAQ: ONCE) and BioMarin (NASDAQ: BMRN) presented promising data for gene therapy drugs that could change the way....
3 Top Pharmaceutical Dividend Stocks to Buy Now
Income investors have favored the pharmaceutical sector for decades. That makes sense since drugs tend to enjoy high margins and are needed in good times and bad. These factors allow pharma....
This Possible Dog of the Dow Just Got Even More Interesting
If you invest in the Dogs of the Dow every year, you could end up buying Pfizer (NYSE: PFE) on Jan. 1. The strategy calls for buying the top 10 highest dividend-yielding stocks in the Dow Jones....
Why 2017 Was a Year to Remember for Johnson & Johnson
With less than two weeks remaining in 2017, Johnson & Johnson (NYSE: JNJ) is on track to have its second-best year of the century so far for stock performance. The healthcare giant's share....
The 5 Best-Selling Drugs of 2017
We spent $328.6 billion on prescription drugs in 2016 -- and that's just the United States. The amount will no doubt be higher when the books are closed on 2017.Payers and patients across the....
3 Top Dividend Aristocrats to Buy for 2018
It's quite an honor for a stock to land on the list of Dividend Aristocrats. Income investors like the stability of large-cap stocks that have not only paid out but also increased their dividends....
Better Buy: Johnson & Johnson vs. Merck
This big pharma claims one of the hottest cancer drugs around. But it also faces challenges for some of its biggest-selling drugs. Which big pharma is it?Actually, it's two: Johnson & Johnson....
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value
Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent....
What to Expect From AbbVie Inc. in 2018
In the words of the legendary James Brown, I feel good.Early this year, I bought a position in AbbVie (NYSE: ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm....
Is the Stock Market Overpriced? Yes -- but Not These 3 Sectors
Is the stock market overpriced? Consider that the historical price-to-earnings (P/E) ratio for the S&P 500 over the past 146 years is 15.6. The current earnings multiple is over 25.5 -- more....
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that.....